文献速递类风湿关节炎

类风湿关节炎停用JAK抑制剂后按原因分层的治疗留存:ANSWER队列研究

Reasons-stratified treatment retention after JAK inhibitor discontinuation in rheumatoid arthritis: the ANSWER cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2026-10-20

基于ANSWER队列500个治疗疗程,比较类风湿关节炎患者停用JAK抑制剂后改用TNFi、aIL-6R、CTLA4-Ig或JAKi的留存与疾病活动轨迹。因无效停药后CTLA4-Ig因无效停药风险显著高于JAKi(HR 2.83),因毒性不良事件停药后TNFi和aIL-6R的毒性不良事件相关停药风险低于JAKi。12个月CDAI轨迹组间无显著差异。

要点

  • 因无效停用JAKi后,CTLA4-Ig因无效停药风险高于JAKi(HR 2.83)。
  • 因毒性不良事件停用JAKi后,TNFi和aIL-6R的毒性不良事件相关停药风险低于JAKi。
  • 各组12个月CDAI轨迹无显著差异。

核心结论

  • 停用JAKi后的最优治疗策略可能取决于既往停药原因。
  • 因无效停药后,JAKi循环、TNFi和aIL-6R可能是合理选择。
  • 因毒性不良事件停药后,TNFi和aIL-6R的后续毒性不良事件相关停药风险低于JAKi循环。

研究设计与样本

  • ANSWER队列研究,分析500个治疗疗程,均为停用JAKi后启动后续b/tsDMARDs的类风湿关节炎患者。
  • 后续治疗分为TNFi、aIL-6R、CTLA4-Ig和JAKi四类。
  • 按既往JAKi停药原因分层,采用Kaplan-Meier和多变量Cox分析评估药物留存。
  • 采用混合效应模型分析12个月CDAI变化。

主要发现

  • 因无效停用JAKi后,CTLA4-Ig因无效停药风险显著高于后续JAKi(HR 2.83,95% CI 1.20-6.70)。
  • 因毒性不良事件停用JAKi后,TNFi和aIL-6R的毒性不良事件相关停药风险低于JAKi。
  • 总体CTLA4-Ig因无效停药风险较高(HR 2.57,95% CI 1.46-4.54),排除非毒性原因和缓解后的总停药风险也较高(HR 1.77,95% CI 1.02-3.07)。
  • 12个月CDAI轨迹在各治疗组间无显著差异。

关键数值与推荐

  • 因无效停用JAKi后,CTLA4-Ig对比后续JAKi因无效停药的HR为2.83(95% CI 1.20-6.70)。
  • 总体CTLA4-Ig因无效停药的HR为2.57(95% CI 1.46-4.54),排除非毒性原因和缓解后总停药的HR为1.77(95% CI 1.02-3.07)。

临床怎么用

  • 停用JAKi后应根据停药原因选择后续b/tsDMARD:因无效停药可考虑JAKi循环、TNFi或aIL-6R。
  • 因毒性不良事件停用JAKi后,TNFi和aIL-6R可能优于JAKi循环。
  • CTLA4-Ig在因无效停用JAKi后的患者中因无效停药风险较高,需谨慎选用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the retention and disease activity trajectories of subsequent biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) after Janus kinase inhibitor (JAKi) discontinuation in patients with rheumatoid arthritis (RA). METHODS: We analysed 500 treatment courses (TCs) from the ANSWER cohort in which subsequent b/tsDMARDs were initiated after JAKi discontinuation. Subsequent treatments were classified as TNF inhibitors (TNFi), anti-IL-6 receptor antibodies (aIL-6R), CTLA4-Ig and JAKi. Drug retention was stratified by the reason for prior JAKi discontinuation and evaluated using Kaplan-Meier and multivariable Cox analyses. Changes in Clinical Disease Activity Index (CDAI) over 12 months were analysed using mixed-effects models for repeated measures. RESULTS: After prior JAKi discontinuation due to ineffectiveness, CTLA4-Ig was associated with a significantly higher risk of discontinuation due to ineffectiveness than subsequent JAKi (HR 2.83, 95% CI 1.20-6.70). Among TCs in which the prior JAKi was discontinued due to toxic adverse events (AEs), TNFi and aIL-6R were associated with lower risks of toxic AE-related discontinuation than JAKi. Overall CTLA4-Ig was associated with higher risks of discontinuation due to ineffectiveness (HR 2.57, 95% CI 1.46-4.54) and total discontinuation excluding non-toxic reasons and remission (HR 1.77, 95% CI 1.02-3.07). CDAI trajectories over 12 months did not differ significantly between treatment groups. CONCLUSION: The optimal treatment strategy after JAKi discontinuation may depend on the reason for prior discontinuation. JAKi cycling, TNFi and aIL-6R may be reasonable after ineffectiveness, whereas after toxic AEs, TNFi and aIL-6R were associated with lower risks of subsequent toxic AE-related discontinuation than JAKi cycling.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fujisawa Y, Watanabe R, Yano Y, et al. Reasons-stratified treatment retention after JAK inhibitor discontinuation in rheumatoid arthritis: the ANSWER cohort study. Rheumatology (Oxford). 2026. PMID: 42900496. doi:10.1093/rheumatology/keag587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。